Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant

Por Barbour, S., Smit, T., Wang, X., Powers, D., Arora, S., Kansra, V., Aapro, M., Herrstedt, J.
Publicado no Ann Oncol (2017)

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients

Por van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., Beijnen, J. H.
Publicado no Cancer Chemother Pharmacol (2017)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients

Por van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., Beijnen, J. H.
Publicado no Cancer Chemother Pharmacol (2017)

Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Por van Andel, Lotte, Zhang, Z., Lu, S., Kansra, V., Agarwal, S., Hughes, L., Tibben, M. M., Gebretensae, A., Lucas, L., Hillebrand, M. J. X., Rosing, H., Schellens, J. H. M., Beijnen, J. H.
Publicado no Invest New Drugs (2017)